Bezlotoxumab was discovered to be related to decreased danger for recurrent Clostridioides difficile an infection (CDI) amongst sufferers having undergone stable organ or hematopoietic cell transplantation, in keeping with the outcomes of a examine revealed in Open Discussion board Infectious Illnesses.
This retrospective cohort examine analyzed affected person information from the College of Colorado Hospital collected between 2015 and 2019. Sufferers (N=95) who had undergone stable organ or hematopoietic cell transplantation have been assessed for medical traits and recurrent CDI.
The imply age of sufferers was 53±15 years, 56% have been males, transplant occurred a median of two.7 years (interquartile vary [IQR], 0.4-7.5) beforehand, sufferers had historical past of three CDI infections (IQR, 2-3), and 39 (41%) had undergone remedy with bezlotoxumab. Transplants have been of hematopoietic cells (n=21), kidney (n=27), liver (n=24), coronary heart (n=11), lung (n=3), and a number of organs (n=8).
In contrast with those that didn’t endure remedy with bezlotoxumab, fewer sufferers who have been handled with bezlotoxumab have been admitted to the intensive care unit (3% vs 21%; P =.01) or had extreme CDI (13% vs 32%; P =.04). Bezlotoxumab was extra regularly used as an prolonged, tapered CDI remedy (58% vs 23%; P <.01).
At 90 days, no important variations have been noticed for CDI recurrence (16% vs 29%; P =.13), dying (0% vs 5%; P =.27), hospital readmission (47% vs 50%; P =.67), or exacerbation of coronary heart failure (0% vs 8%; P =.49) among the many bezlotoxumab and standard-of-care cohorts, respectively.
Recurrence of CDI at 90 days was related to variety of earlier CDI episodes (odds ratio [OR], 1.48; 95% CI, 1.12-1.95; P =.01) and bezlotoxumab publicity (OR, 0.28; 95% CI, 0.08-0.91; P =.03).
Bezlotoxumab was properly tolerated amongst all however 1 affected person, who had infusion-related nausea and discontinued use.
This examine ought to be thought-about as exploratory because it was underpowered.
These information indicated use of bezlotoxumab was related to decreased danger for CDI recurrence amongst sufferers who had undergone stable organ or hematopoietic cell transplantation.
Disclosure: A number of authors declared affiliations with business. Please check with the unique article for a full record of disclosures.
Johnson TM, Howard AH, Miller MA, et al. Effectiveness of bezlotoxumab for prevention of recurrent Clostridioides difficile an infection amongst transplant recipients. Open Discussion board Infect Dis. Revealed June 4, 2021. doi:10.1093/ofid/ofab294